- 1 Information about Lixisenatide
- 2 Liver safety of Lixisenatide
- 3 Mechanism of action of Lixisenatide
- 4 FDA approval information for Lixisenatide
- 5 Brand name for Lixisenatide
- 6 Dosage and administration for Lixisenatide
- 7 Side effects of Lixisenatide
- 8 Articles on Lixisenatide
- 9 Learn more about Lixisenatide
Information about Lixisenatide
Lixisenatide is a recombinant DNA produced polypeptide analogue of human glucagon-like peptide-1 (GLP-1) which is used in combination with diet and exercise in the therapy of type 2 diabetes, either alone or in combination with other antidiabetic agents.
Liver safety of Lixisenatide
Therapy with lixisenatide has not been associated with serum enzyme elevations or with episodes of clinically apparent liver injury.
Mechanism of action of Lixisenatide
Lixisenatide (lix" i sen' a tide) is a glucagon-like peptide-1 (GLP-1) analogue (also called a GLP-1 receptor agonist) that acts like the native gastrointestinal hormone (incretin) to increase insulin secretion. Lixisenatide, like other GLP-1 analogues, also suppress glucagon production and slows gastric emptying, features that may increase the beneficial effects in type 2 diabetes. Lixisenatide is a recombinant DNA-produced polypeptide that is 44 amino acids in length with a single proline substitution and a modified C-terminus of six lysine molecules that makes it relatively resistant to degradation by dipeptidyl peptidase 4 (DPP4) and extends its half-life allowing for once daily dosing. In multiple preregistration clinical trials, lixisenatide was shown to improve glycemic control and lower HbA1c levels in patients with inadequately controlled type 2 diabetes.
FDA approval information for Lixisenatide
Lixisenatide was approved in the United States in 2016 and current indications are for management of glycemic control in adults with type 2 diabetes in combination with diet and exercise, with or without other oral hypoglycemic agents or insulin.
Brand name for Lixisenatide
Lixisenatide is available under the brand name Adlyxin in multiuse prefilled pens (50 and 100 µg/mL).
Dosage and administration for Lixisenatide
The recommended starting dose is 10 µg once daily which after 2 weeks can be increased to 20 µg once daily. A fixed combination of lixisenatide (33 µg/mL) with insulin glargine (100 units/mL) is also available under the brand name Soliqua (100/33).
Side effects of Lixisenatide
Lixisenatide is generally well tolerated, but side effects can be dose limiting and include injection site reactions, diarrhea, nausea, vomiting, dizziness, headache, fatigue and hypoglycemia. Rare adverse events include pancreatitis, severe hypoglycemia, acute renal injury and hypersensitivity reactions.
- Alpha-Glucosidase Inhibitors
- Incretin-Based Drugs
- Metiglinide Analogues
- Sodium Glucose Cotransporter-2 (SGLT-2) Inhibitors